<DOC>
	<DOC>NCT00461682</DOC>
	<brief_summary>SB-705498 has demonstrated efficacy in several preclinical and human experimental pain models. This study will investigate the efficacy of SB-705498 in patients with rectal pain. This will be a double-blind, placebo-controlled, two-way crossover study. 21 patients with faecal urgency (Group 1), and 21 patients with IBS (Group 2) will complete this study.</brief_summary>
	<brief_title>Sb-705498 Rectal Pain Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Female/male aged 1865. Women of child bearing potential must use an effective method of contraception Faecal urgency as defined by Chan ECG, which has no abnormalities Normal Clinical labs Informed consent and understand protocol requirements IBS subjects: Has irritable bowel syndrome (IBS) as defined by Rome II criteria Rectal hyperalgesia Any clinical or biological abnormality found at screen (other than those related to the disease under investigation) History of alcohol, substance or drug abuse Uncontrolled hypertension A history or presence of cardiovascular risk factors Participation in a trial within 3 months before the start of the study History of allergy Unable to withdraw from analgesic medications for their rectal hyperalgesia (opioiddependent patients can be included if they are willing to withdraw from their opiate medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>TRPV1 antagonist</keyword>
	<keyword>Fecal Urgency</keyword>
	<keyword>rectal pain</keyword>
	<keyword>IBS</keyword>
</DOC>